KR940003564A - 특정 질환의 예방 및 치료용 약제를 제조하기 위한 c1- 불활성제화제의 용도 - Google Patents
특정 질환의 예방 및 치료용 약제를 제조하기 위한 c1- 불활성제화제의 용도 Download PDFInfo
- Publication number
- KR940003564A KR940003564A KR1019930016325A KR930016325A KR940003564A KR 940003564 A KR940003564 A KR 940003564A KR 1019930016325 A KR1019930016325 A KR 1019930016325A KR 930016325 A KR930016325 A KR 930016325A KR 940003564 A KR940003564 A KR 940003564A
- Authority
- KR
- South Korea
- Prior art keywords
- prevention
- treatment
- surgery
- ooou
- capillary leakage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 심한 화상(burns 또는 Scalds), 다외상, 칙외 순환의 상태에서의 수술, 시토킨, 내인성 조정기, 조정기 하이브리드 및 유전 공학에 의해 제조된 성장 인자를 사용할 경우 모세혈관 누출 증상(전신적 일헐(extravasation)) 및 순환쇼크(고질적 저혈압) 및 치료적 또는 예방적 징후를 나타내는 골수 이식 수술시간의 정맥-폐쇄 질환의 예방 및 치료용 약제를 제조하기 위한 Cl-불활성화제의 용도에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (5)
- 심한 화상(burns또는Scalds), 다외상, 체회순환의 상태에서의 수술, 시토킨, 내인성 조정기, 조정기 하이브리드 및 유전 공학에 의해 제조된 성장 인자를 사용할 경우 모세혈관 눅출증상(전신적 일헐(extravasation)및 순환 쇼크(고질적 저혈압) 및 치료적 또는 예방적 징후를 나타내는 골수 이식 수술시 모세혈관 누출 증상 및 간의 정맥-궤쇄 질환의 예방 및 치료용 약제를 제조하기 위한 Cl-불즐성화제의 용도.
- 제1항에 있어서, Cl-불존성화제를 1일 체중 1kg당 1내지 5, OOOU, 바람직하게는 5내지 1,070u를 함유하는 조성물을 제조하는 용도.
- 제1항에 있어서, Cl-불활성화제를 1일 체중 Ik9당 1내지 300,OOOU, 바람직하게는 50내지 60,000를 함유하는 고체 조성물을 제조하는 용도.
- 제1항에 있어서, 정맥내, 근육내 및 피하용 조성물을 바람직하게는 약제학적 보조제와함께 제조하는 용도.
- 제4항에 있어서, 경구 또는 직장용 조성물을 제조하는 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4227762.0 | 1992-08-24 | ||
DE4227762A DE4227762A1 (de) | 1992-08-24 | 1992-08-24 | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
Publications (2)
Publication Number | Publication Date |
---|---|
KR940003564A true KR940003564A (ko) | 1994-03-12 |
KR100290753B1 KR100290753B1 (ko) | 2001-09-17 |
Family
ID=6466096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930016325A KR100290753B1 (ko) | 1992-08-24 | 1993-08-23 | C1-불활성화제를포함하는약제학적조성물 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5939389A (ko) |
EP (1) | EP0586909A3 (ko) |
JP (1) | JPH06157343A (ko) |
KR (1) | KR100290753B1 (ko) |
AU (1) | AU671287B2 (ko) |
CA (1) | CA2104636C (ko) |
DE (2) | DE4227762A1 (ko) |
IL (1) | IL106776A0 (ko) |
NO (1) | NO933000L (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4227762A1 (de) * | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
JP2000507204A (ja) * | 1995-12-18 | 2000-06-13 | ステイヒテイング・サンキン・ブロードボールジーニング | C1―インヒビターの補体及び血液凝固阻害特性の強化 |
US20040152635A1 (en) * | 1998-06-22 | 2004-08-05 | Albrecht Groner | Modified C1 esterase inhibitor for blocking the infectiousness of HIV |
DE19827750C1 (de) | 1998-06-22 | 1999-07-29 | Centeon Pharma Gmbh | Verfahren zum Abtrennen von HIV aus einer Flüssigkeit |
AU2006203549B2 (en) * | 2000-01-31 | 2008-10-09 | Pharming Intellectual Property B.V. | C1 inhibitor produced in the milk of transgenic mammals |
DE122011000002I1 (de) * | 2000-01-31 | 2011-05-05 | Pharming Intellectual Pty Bv | Humaner c1 inhibitor hergestellt in der milch transgener säugetiere |
US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
ES2830499T3 (es) | 2003-05-16 | 2021-06-03 | Pharming Intellectual Property B V | Inhibidor de C1 con una semivida corta para un tratamiento transitorio |
US8703136B2 (en) | 2006-10-10 | 2014-04-22 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
EP2758076B1 (en) | 2011-09-24 | 2018-12-12 | CSL Behring GmbH | Combination therapy using immunoglobulin and c1-inhibitor |
CA2858984C (en) | 2011-12-22 | 2021-01-05 | Csl Behring Gmbh | Use of c1-inhibitor for the treatment of secondary edema of the central nervous system |
ES2609070T3 (es) * | 2013-02-28 | 2017-04-18 | Csl Behring Gmbh | Agente terapéutico para el embolismo de líquido amniótico |
KR102403299B1 (ko) | 2013-03-08 | 2022-06-03 | 체에스엘 베링 게엠베하 | 원격 허혈-재관류 손상의 치료 및 예방 |
KR20160026905A (ko) | 2013-06-28 | 2016-03-09 | 체에스엘 베링 게엠베하 | 인자 xii 억제제 및 c1-억제제를 이용한 병용 치료요법 |
US10532087B2 (en) | 2015-06-03 | 2020-01-14 | Children's Hospital Medical Center | Compositions and methods for treating neonatal biliary atresia |
EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
WO2018037046A1 (en) | 2016-08-23 | 2018-03-01 | Csl Behring Gmbh | Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency |
US20200276283A1 (en) | 2017-09-15 | 2020-09-03 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
KR20230110563A (ko) | 2020-11-20 | 2023-07-24 | 체에스엘 베링 게엠베하 | 항체 매개 거부 반응의 치료 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3228502A1 (de) * | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung des c1-inaktivators und seine verwendung |
US5271931A (en) * | 1988-09-14 | 1993-12-21 | The Scripps Research Institute | Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6 |
US5030578A (en) * | 1989-07-10 | 1991-07-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Process for the purification of C1-inhibitor |
EP0512090B2 (en) * | 1990-10-16 | 2006-11-22 | Sonoran Desert Chemicals LLC | Treatment of inflammation |
WO1992022320A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
DE4227735C2 (de) * | 1992-08-21 | 1995-10-12 | Leybold Ag | Anordnung zum berührungslosen Messen der Dicke von Schichten |
DE4227762A1 (de) * | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
-
1992
- 1992-08-24 DE DE4227762A patent/DE4227762A1/de not_active Withdrawn
- 1992-08-24 DE DE4244735A patent/DE4244735A1/de not_active Withdrawn
-
1993
- 1993-08-11 EP EP93112844A patent/EP0586909A3/de not_active Ceased
- 1993-08-23 JP JP5207334A patent/JPH06157343A/ja active Pending
- 1993-08-23 NO NO933000A patent/NO933000L/no not_active Application Discontinuation
- 1993-08-23 CA CA002104636A patent/CA2104636C/en not_active Expired - Lifetime
- 1993-08-23 AU AU44778/93A patent/AU671287B2/en not_active Ceased
- 1993-08-23 IL IL106776A patent/IL106776A0/xx unknown
- 1993-08-23 KR KR1019930016325A patent/KR100290753B1/ko not_active IP Right Cessation
-
1997
- 1997-05-12 US US08/854,365 patent/US5939389A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0586909A2 (de) | 1994-03-16 |
EP0586909A3 (de) | 1995-04-05 |
AU4477893A (en) | 1994-03-03 |
AU671287B2 (en) | 1996-08-22 |
DE4244735A1 (de) | 1994-03-31 |
NO933000D0 (no) | 1993-08-23 |
JPH06157343A (ja) | 1994-06-03 |
DE4227762A1 (de) | 1994-03-03 |
CA2104636A1 (en) | 1994-02-25 |
CA2104636C (en) | 2003-11-11 |
KR100290753B1 (ko) | 2001-09-17 |
NO933000L (no) | 1994-02-25 |
IL106776A0 (en) | 1993-12-08 |
US5939389A (en) | 1999-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR940003564A (ko) | 특정 질환의 예방 및 치료용 약제를 제조하기 위한 c1- 불활성제화제의 용도 | |
KR900701282A (ko) | 심장 또는 뇌의 허혈성 질환의 치료, 예방제 | |
HK1048251A1 (zh) | 用於治療青光眼或眼壓過高的前列腺素衍生物 | |
IL75851A (en) | Pharmaceutical composition comprising xanthine derivatives and o-acetyl-salicylic acid or its pharmacologically tolerated salts and its preparation | |
KR0141913B1 (en) | Anti-virus agents | |
CA2123049A1 (en) | Pharmaceutical containing the p40 subunit of interleukin 12 | |
DE69930271T8 (de) | Medizinische zusammensetzungen zur behandlung von augenerkrankungen | |
DK0920865T3 (da) | Farmaceutiske sammensætninger indeholdende norastemizol | |
Akpek et al. | Epidural anesthesia for renal transplantation: a preliminary report | |
SE8105561L (sv) | Anvendning av pyridoxin-alfa-ketoglutarat vid profylax av hypermjolksyraemi | |
NZ506408A (en) | Pharmaceutical compositions | |
KR950007848A (ko) | (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법 | |
KR950703527A (ko) | 프로스타글란딘 유도체 | |
EP0459377B1 (en) | Use of E1 prostaglandin to cure male erectile inpotence | |
CA1217717A (en) | Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction | |
KR890012942A (ko) | 5-치환된 오르니틴 유도체 | |
KR950701627A (ko) | 벤조티아졸 화합물, 그의 제조방법 및 용도(benzothiazole compound, process for producing the same, and use thereof) | |
KR950702544A (ko) | 비페닐메탄 유도체 및 이를 함유하는 약제 | |
KR980002033A (ko) | 트리아졸 유도체 또는 그 염 | |
KR910000142A (ko) | 신경보호제로서의 5-페닐-2- 푸란 에스테르, 아미드 및 케톤의 신규한 용도 | |
KR970064604A (ko) | 벤조피란 유도체 및 그의 심장질환 치료제로서의 용도 | |
CA2065889A1 (en) | Increasing the choroidal blood flow | |
US2592149A (en) | Therapeutic preparation comprising benzyl cinnamate and vitamin a | |
US2676961A (en) | Procaine-penicillin preparation | |
KR890001555A (ko) | 요산 배설용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130220 Year of fee payment: 13 |
|
EXPY | Expiration of term |